History Repeats: Will US Stelara Settlements Follow Humira’s Lead?
Adalimumab Example Could Provide A Playbook For Settlements Over Ustekinumab Biosimilars
Executive Summary
Hopes are rising that Johnson & Johnson will be able to emulate AbbVie’s success in delaying US biosimilar competition to its top-selling Humira by using a similar settlement strategy with its anti-IL12/IL23 blockbuster Stelara.